Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Yahoo Finance host Madison Mills tracks today's top moving stocks and biggest market stories in this Market Minute, including ...

Novo Nordisk has launched a late-stage trial for its obesity drug candidate, CagriSema, aiming to restore market confidence ...

Novo Nordisk initiates a late-stage trial of CagriSema, a next-generation obesity drug, to address potential doubts from ...

Shares of the electric-vehicle maker continued their rebound from the rout last week that was sparked by Elon Musk's fallout with President Trump. The stock rose more than 5% . ↗️ [Taiwan Semiconducto ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

Denmark-based multinational pharmaceutical company Novo Nordisk will make Wegovy, its approved weight-loss treatment for ...